Measurements of thromboxane production and their clinical significance in coronary heart disease

Thrombosis and Haemostasis

Volumn 108, Issue 1, 2012, Pages 6-8

  Renda, Giulia ^a   De Caterina, Raffaele ^a,b  

^a UNIVERSITY OF CHIETI   (Italy)

^b FONDAZIONE TOSCANA GABRIELE MONASTERIO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; ICOSANOID; THROMBOSPONDIN 1; THROMBOXANE; THROMBOXANE A2; THROMBOXANE B2;

ARTICLE; ATHEROSCLEROSIS; DISEASE SEVERITY; HUMAN; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; PRIORITY JOURNAL; PROTEIN SYNTHESIS; THROMBOCYTE ACTIVATION;

ACUTE CORONARY SYNDROME; ASPIRIN; BIOLOGICAL MARKERS; FEMALE; HUMANS; MALE; THROMBOXANE A2;

EID: 84863642402     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH12-05-0311     Document Type: Article

References (23)

1. Kuliczkowski W, Witkowski A, Polonski L, et al. Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J 2009; 30: 426-435.
2. Sibbing D, Byrne RA, Bernlochner I, Kastrati A. High platelet reactivity and clinical outcome - fact and fiction. Thromb Haemost 2011; 106: 191-202.
3. Samuelsson B, Goldyne M, Granstrom E, Hamberg M, Hammarstrom S, Malmsten C. Prostaglandins and thromboxanes. Annu Rev Biochem 1978; 47: 997-1029.
4. Hamberg M, Svensson J, Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 1975; 72: 2994-2998.
5. Patrono C. Biosynthesis and pharmacological modulation of thromboxane in humans. Circulation 1990; 81: I12-I15; discussion I22-23.
6. Patrono C, Ciabattoni G, Pugliese F, et al. Estimated rate of thromboxane secretion into the circulation of normal humans. J Clin Invest 1986; 77: 590-594.
7. Catella F, Healy D, Lawson JA, et al. 11-Dehydrothromboxane B2: a quantitative index of thromboxane A2 formation in the human circulation. Proc Natl Acad Sci USA 1986; 83: 5861-5865.
8. Ciabattoni G, Pugliese F, Davi G, et al. Fractional conversion of thromboxane B2 to urinary 11-dehydrothromboxane B2 in man. Biochim Biophys Acta 1989; 992: 66-70.
9. Cattaneo M. Laboratory detection of 'aspirin resistance': what test should we use (if any)? Eur Heart J 2007; 28: 1673-1675.
10. FitzGerald GA, Healy C, Daugherty J. Thromboxane A2 biosynthesis in human disease. Fed Proc 1987; 46: 154-158.
11. Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007; 357: 2482-2494.
12. Eikelboom JW, Hirsh J, Weitz JI, et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105: 1650-1655.
13. Santilli F, Romano M, Recchiuti A, et al. Circulating endothelial progenitor cells and residual in vivo thromboxane biosynthesis in low-dose aspirintreated polycythemia vera patients. Blood 2008; 112: 1085-1090.
14. Rocca B, Secchiero P, Ciabattoni G, et al. Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci U S A 2002;99:7634-7639.
15. Henry P, Vermillet A, Boval B, Guyetand C, Petroni T, Dillinger JG, Sideris G, Sollier CB, Drouet L. 24-hour time-dependent aspirin efficacy in patients with stable coronary artery disease. Thromb Haemost 2011; 105: 336-344.
16. O'Donnell CJ, Larson MG, Feng D, et al. Genetic and environmental contributions to platelet aggregation: the Framingham heart study. Circulation 2001; 103: 3051-3056.
17. Feher G, Feher A, Pusch G, et al. The genetics of antiplatelet drug resistance. Clin Genet 2009; 75: 1-18.
18. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001; 345: 1809-1817.
19. Renda G, Tacconelli S, Capone ML, et al. Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease. Clin Pharmacol Ther 2006; 80: 264-274.
20. Curtis JP, Krumholz HM. The case for an adverse interaction between aspirin and non-steroidal anti-inflammatory drugs: is it time to believe the hype? J Am Coll Cardiol 2004; 43: 991-993.
21. Niccoli G, Giubilato S, Leo A, et al. Predictors of thromboxane levels in patients with Non-ST Elevation Acute Coronary Syndromes on chronic aspirin therapy. Thromb Haemost 2012; 108: 133-139.
22. Niccoli G, Giubilato S, Russo E, et al. Plasma levels of thromboxane A2 on admission are associated with no-reflow after primary percutaneous coronary intervention. Eur Heart J 2008; 29: 1843-1850.
23. Spectre G, Arnetz L, Ostenson CG, et al. Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro-or macrovascular complications. Thromb Haemost 2011; 106: 491-499